AstraZeneca to buy US-listed Fusion Pharma for $2bn

By

Sharecast News | 19 Mar, 2024

Updated : 11:51

23:32 08/11/24

  • 21.55
  • 0.00%0.00
  • Max: 21.55
  • Min: 21.55
  • Volume: 0
  • MM 200 : n/a

AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.

AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.

Reporting by Frank Prenesti for Sharecast.com

Last news